These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28525795)

  • 61. New insights in research about acute ischemic myocardial injury and inflammation.
    Vincent A; Lattuca B; Merlet N; Sportouch-Dukhan C; Barrère-Lemaire S
    Antiinflamm Antiallergy Agents Med Chem; 2013; 12(1):47-54. PubMed ID: 23286292
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
    Oslund RC; Cermak N; Gelb MH
    J Med Chem; 2008 Aug; 51(15):4708-14. PubMed ID: 18605714
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Structural basis for functional selectivity and ligand recognition revealed by crystal structures of human secreted phospholipase A
    Hou S; Xu T; Xu J; Qu L; Xu Y; Chen L; Liu J
    Sci Rep; 2017 Sep; 7(1):10815. PubMed ID: 28883454
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of acadesine in clinical myocardial protection.
    Alkhulaifi AM; Pugsley WB
    Br Heart J; 1995 Apr; 73(4):304-5. PubMed ID: 7756061
    [No Abstract]   [Full Text] [Related]  

  • 65. Synthesis of N-(trifluoromethyl-2-pyridinyl)arenesulfonamides as an inhibitor of secretory phospholipase A₂.
    Nakayama H; Morita Y; Kimura H; Ishihara K; Akiba S; Uenishi J
    Chem Pharm Bull (Tokyo); 2011; 59(6):783-6. PubMed ID: 21628920
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders.
    Phillis JW; O'Regan MH
    Brain Res Brain Res Rev; 2004 Jan; 44(1):13-47. PubMed ID: 14739001
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibition of type II phospholipase A(2) by LY329722 attenuates ischemia and reperfusion injury of canine livers.
    Ogata K; Jin MB; Suzuki T; Taniguchi M; Shimamura T; Fukai M; Furukawa H; Todo S
    Transplant Proc; 2001; 33(1-2):860-1. PubMed ID: 11267103
    [No Abstract]   [Full Text] [Related]  

  • 68. Antisense inhibition of phospholipase A2: a new approach for already tested therapeutic targets for the treatment of sepsis*.
    Touqui L
    Crit Care Med; 2012 Jul; 40(7):2250-1. PubMed ID: 22710222
    [No Abstract]   [Full Text] [Related]  

  • 69. Letter by Krijnen et al regarding article, "The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial".
    Krijnen PA; Hack CE; Niessen HW
    Circulation; 2011 Sep; 124(11):e298; author reply e299-300. PubMed ID: 21911792
    [No Abstract]   [Full Text] [Related]  

  • 70. Loganin: A potential pharmacological agent for myocardial ischemia-reperfusion injury.
    Li Q; Zhao L; Wang C; Liu Z; Lu C
    Int J Cardiol; 2024 Mar; 398():131650. PubMed ID: 38072131
    [No Abstract]   [Full Text] [Related]  

  • 71. Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges.
    Ren J; Zhang Y
    Curr Drug Targets; 2017; 18(15):1687-1688. PubMed ID: 29070009
    [No Abstract]   [Full Text] [Related]  

  • 72. Exosomes-ADMS: A novel therapy thought in myocardial ischemia reperfusion injury.
    Fan ZX; Yang J
    Int J Cardiol; 2017 Jul; 239():11. PubMed ID: 28560958
    [No Abstract]   [Full Text] [Related]  

  • 73. Commentary: Calpain inhibition: A novel strategy to treat chronic myocardial ischemia.
    Lazar HL
    J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e29-e30. PubMed ID: 31926683
    [No Abstract]   [Full Text] [Related]  

  • 74. Secretory phospholipase A2 group XIIBs play potential roles in intestine antibacterial responses in seahorse.
    Xiao W; Qin G; Zhang Y; Zhang B; Li T; Chen Z; Lin Q
    J Fish Dis; 2022 Jul; 45(7):1059-1063. PubMed ID: 35352834
    [No Abstract]   [Full Text] [Related]  

  • 75. Advances in Cardiovascular Pharmacology: Protocol Design and Methodology. Proceedings of the 11th annual symposium. Atherosclerosis and Drug Development for Ischemic Heart Disease.
    Borer JS
    J Clin Pharmacol; 1992 Sep; 32(9):848-66. PubMed ID: 1430304
    [No Abstract]   [Full Text] [Related]  

  • 76. Corrigendum to: Acute Lung Injury in A Rat Model Of Intestinal Ischemia-Reperfusion: The Potential Time Depended Role Of Phospholipases: [Journal of Surgical Research 147 (2008) 108-116].
    Kostopanagiotou G; Avgerinos E; Kostopanagiotou K; Arkadopoulos N; Andreadou I; Diamantopoulou K; Lekka M; Smyrniotis V; Nakos G
    J Surg Res; 2021 Jul; 263():291. PubMed ID: 34053697
    [No Abstract]   [Full Text] [Related]  

  • 77. The pathological mechanism of copper overload in myocardial ischemia-reperfusion injury.
    Zhao S; Liu Y; Li C
    Asian J Surg; 2024 Jun; ():. PubMed ID: 38937244
    [No Abstract]   [Full Text] [Related]  

  • 78. Lethal Myocardial Reperfusion Injury: Fact or Fiction?
    Werns SW
    J Thromb Thrombolysis; 1997 Jan; 4(1):47-49. PubMed ID: 10639223
    [No Abstract]   [Full Text] [Related]  

  • 79. Involvement of Nrf2 in myocardial ischemia and reperfusion injury.
    Shen Y; Liu X; Shi J; Wu X
    Int J Biol Macromol; 2019 Mar; 125():496-502. PubMed ID: 30468811
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of intrathecal sufentanil preconditioning against myocardial ischemia-reperfusion injury.
    Tire Y; Sarkilar G; Esen H; Onoglu R; Uzun ST
    Bratisl Lek Listy; 2018; 119(4):240-244. PubMed ID: 29663822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.